Pharmaceuticals Industry In India Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The Indian pharmaceutical market encompasses drug discovery, development, manufacturing, and distribution of pharmaceutical products across therapeutic categories including generics, branded formulations, biologics, and active pharmaceutical ingredients. Domestic market consumption is driven by improving access to medicines through government schemes like Ayushman Bharat and expanding private healthcare infrastructure across urban and rural areas. The sector benefits from India's large pool of skilled scientists, competitive manufacturing costs, and a regulatory framework that has evolved to align with global standards while supporting domestic growth.

• •India is the world's third-largest pharmaceutical market by volume and 14th largest by value
• •The domestic market consumes over $20 billion annually with exports adding approximately $25 billion in revenue
• •Over 3,000 pharmaceutical companies and 10,500 manufacturing units operate across the country

Rising healthcare spending from India's growing middle class and aging population is a primary catalyst, as non-communicable diseases such as diabetes, cardiovascular conditions, and respiratory ailments increase in prevalence. Government policy support through initiatives like the Production Linked Incentive Scheme for pharmaceuticals and expanded health insurance coverage under national programs stimulates both domestic demand and export competitiveness. The global shift toward pharmaceutical outsourcing continues as Western markets seek cost-effective manufacturing partners, with India capturing significant market share in regulated markets including the United States, European Union, and Japan.

• •Chronic disease burden affects over 50% of India's population, driving sustained medicine demand
• •Pharmaceutical exports reached approximately $25 billion in recent years, with the US and EU as top destinations
• •Healthcare spending in India is projected to reach 5% of GDP by 2025, up from around 3% a decade earlier

The market divides into formulations, bulk drugs, and biologics, with formulations commanding the majority share through both generic and branded segments. Indian pharmaceutical manufacturing is geographically concentrated in key clusters including Hyderabad, Ahmedabad, Mumbai, and Bangalore, with additional manufacturing hubs emerging in regions with growing industrial infrastructure. Western and southern states dominate production capacity, while northern and eastern regions represent growing consumption markets as healthcare access expands.

• •Generics account for approximately 70% of domestic market sales, with branded generics commanding premium pricing
• •Biologics and biosimilars represent the fastest-growing segment at projected compound annual growth above 20%
• •Major manufacturing hubs include Gujarat, Andhra Pradesh, Telangana, and Maharashtra, collectively hosting over 60% of pharma units

What are the recent trends and outlook?

Specialty pharmaceuticals and biologics are emerging as the primary growth frontier as India develops capabilities in biosimilars, vaccines, and advanced drug delivery systems. Digital health integration, including telemedicine platforms and AI-assisted drug discovery, is reshaping both manufacturing efficiency and patient access across the sector. Continued regulatory strengthening, investment in research and development, and expansion into emerging markets position India to sustain its 11.75% annual growth trajectory through 2030, with projections suggesting the market could exceed $130 billion within the decade.

• •Biosimilar approvals from regulatory agencies have accelerated, with Indian companies filing over 100 pending applications globally
• •R&D spending as a percentage of revenue has been gradually increasing toward international benchmarks, though still below 10% on average
• •The sector is attracting significant private equity and strategic investment as global pharmaceutical companies deepen partnerships with Indian manufacturers